AlloJoin (allogeneic human adipose-derived mesenchymal stem cell therapy) / AbelZeta Pharma - LARVOL DELTA

CBM-MPC-007: Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis (clinicaltrials.gov) - P3 | N=520 | Recruiting | Sponsor: Wuxi Cellular Biopharmaceutical Group Ltd. | Not yet recruiting ➔ Recruiting | Initiation date: Oct 2024 ➔ Feb 2025

Enrollment open • Trial initiation date • Immunology • Osteoarthritis • Pain • Rheumatology

Allogenic Adipose-Derived Mesenchymal Progenitor Cells for the Treatment of Knee Osteoarthritis (clinicaltrials.gov) - P3 | N=488 | Not yet recruiting | Sponsor: Wuxi Cellular Biopharmaceutical Group Ltd.

New P3 trial • Immunology • Osteoarthritis • Pain • Rheumatology

A Clinical Study of Mesenchymal Progenitor Cell Exosomes Nebulizer for the Treatment of Pulmonary Infection (clinicaltrials.gov) - P1/2 | N=60 | Suspended | Sponsor: Ruijin Hospital | Trial completion date: Jul 2023 ➔ Mar 2025 | Recruiting ➔ Suspended | Trial primary completion date: May 2023 ➔ Dec 2024

Gram negative • Trial completion date • Trial primary completion date • Trial suspension • Infectious Disease • Respiratory Diseases

Three-dimensional texture analyses of multi-quantitative relaxation time maps for evaluating cartilage repair with the treatment of allogeneic human adipose-derived mesenchymal progenitor cells. (PubMed, Magn Reson Imaging) - "Texture analysis of the cartilage may allow the detection of compositional variation in cartilage repair with the treatment of allogeneic haMPCs. This technique displays potential applications in understanding the mechanism of stem cell repair of the cartilage and assessing the treatment response."

Journal • Immunology • Osteoarthritis • Pain • Rheumatology

Allogenic Adipose-Derived Mesenchymal Progenitor Cells for the Treatment of Knee Osteoarthritis (clinicaltrials.gov) - P3 | N=488 | Not yet recruiting | Sponsor: Cellular Biomedicine Group Ltd.

New P3 trial • Immunology • Osteoarthritis • Pain • Rheumatology

Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells for the Treatment of Knee Osteoarthritis (clinicaltrials.gov) - P2 | N=106 | Completed | Sponsor: Cellular Biomedicine Group Ltd. | Active, not recruiting ➔ Completed

Trial completion • Immunology • Osteoarthritis • Pain • Rheumatology

Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells for the Treatment of Knee Osteoarthritis (clinicaltrials.gov) - P2 | N=108 | Active, not recruiting | Sponsor: Cellular Biomedicine Group Ltd. | Recruiting ➔ Active, not recruiting | Trial completion date: Jan 2022 ➔ Jun 2023 | Trial primary completion date: Dec 2021 ➔ Jun 2023

Enrollment closed • Trial completion date • Trial primary completion date • Immunology • Osteoarthritis • Pain • Rheumatology

CBM officially announces the launch of Phase 3 clinical trial of AlloJoin, an adipose-derived mesenchymal stem cell product [Google translation] (Sina Corp) - P2 | N=108 | NCT04208646 | Sponsor: Cellular Biomedicine Group Ltd. | "Cellular Biomedicine Group (CBMG), a biopharmaceutical company focused on the development of innovative cell therapies, officially announced today that it has launched the Phase III of AlloJoin®, its allogeneic human-derived adipose-derived mesenchymal progenitor cell injection Clinical Trials. The results of the completed randomized, double-blind, controlled multi-center phase II clinical trial (96-week follow-up) initially show that AlloJion® has relatively good safety and efficacy in the treatment of knee osteoarthritis (KOA)."

New P3 trial • Trial status • CNS Disorders • Osteoarthritis • Pain

Cellular Biomedicine Group Reports Q3 2020 Financial Results and Business Highlights (PRNewswire) - "We are also enrolling patients in China for our off-the-shelf AlloJoin® Phase II trial in the treatment of knee osteoarthritis (KOA). To date we have seen fewer than expected adverse events (AE) and AEs are limited to grades 1 and 2 in the trial participants."

Enrollment status • CNS Disorders • Osteoarthritis • Pain

Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells for the Treatment of Knee Osteoarthritis (clinicaltrials.gov) - P2; N=108; Recruiting; Sponsor: Cellular Biomedicine Group Ltd.; Not yet recruiting ➔ Recruiting; Trial completion date: Oct 2021 ➔ Jan 2022; Initiation date: Dec 2019 ➔ May 2020; Trial primary completion date: Oct 2020 ➔ Dec 2021

Clinical • Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Immunology • Osteoarthritis • Pain • Rheumatology • MRI

A Clinical Study of Mesenchymal Progenitor Cell Exosomes Nebulizer for the Treatment of Pulmonary Infection (clinicaltrials.gov) - P1/2; N=60; Recruiting; Sponsor: Ruijin Hospital

Clinical • New P1/2 trial

A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia (clinicaltrials.gov) - P1; N=24; Completed; Sponsor: Ruijin Hospital; Not yet recruiting ➔ Completed

Clinical • Trial completion • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

CBMG shareholders move to take company private (Bioworld) - Subscription needed.

Enrollment status • Osteoarthritis • Pain

Cellular Biomedicine Group (CBMG) Reports Q2, H1 2020 Financial Results and Business Highlights (PRNewswire) - "'We held a virtual research & development day in July to provide an update on the six clinical programs'...We also continue to enroll patients in China for our off-the-shelf AlloJoin^TM knee osteoarthritis (KOA) Phase II trial."

Enrollment status • Osteoarthritis • Pain

Cellular Biomedicine Group reports Q1 2020 financial results and business highlights (PRNewswire) - "Regarding our regenerative medicine program, with the COVID-19 outbreak tapering off in China, we have resumed patients' enrollment for our knee osteoarthritis (KOA) Phase II allogenic (off the shelf AlloJoin®) stem-cell clinical trial and are in the process of preparing for the Phase II autologous (ReJoin®) trial as well."

Enrollment status • Trial status • CNS Disorders • Immunology • Inflammation • Osteoarthritis • Pain • Rheumatology

Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells for the Treatment of Knee Osteoarthritis (clinicaltrials.gov) - P2; N=108; Not yet recruiting; Sponsor: Cellular Biomedicine Group Ltd.

Clinical • New P2 trial

CBMG: Data from multiple myeloma trial to be presented at ASH… (Yahoo Finance) - "Cellular Biomedicine Group has also initiated a Phase 2 clinical trial in China for AlloJoin®, the company’s allogenic stem cell therapy for knee osteoarthritis, and China’s National Medical Products Administration (NMPA) has accepted the company’s planned Phase 2 trial for ReJoin®, the company’s autologous stem cell therapy for knee osteoarthritis."

New P2 trial • Non-US regulatory • Trial status

Cellular Biomedicine Group hosts meeting with investigators to launch AlloJoin knee osteoarthritis phase II clinical trial (PRNewswire) - "Cellular Biomedicine Group Inc....announced that on September 11, 2019, the Company held a meeting with investigators in Shanghai to launch the Phase II clinical trial for AlloJoin®, an "off-the-shelf" allogenic human adipose-derived mesenchymal progenitor cell therapy product targeting Knee Osteoarthritis (KOA)....The first Phase II clinical trial for KOA that has been permitted by the National Medicinal Products Administration (NMPA) to commence since the NMPA clarified its cell therapy regulations in December 2017 will be conducted by six class 3AAA hospitals in China..."

Non-US regulatory

Cellular Biomedicine Group reports second quarter and first half of 2019 financial results and business highlights (PRNewswire) - "We are actively preparing for a multisite [P II] trial for our AlloJoin® therapy for Knee Osteoarthritis (KOA)..."

New P2 trial